ICU Medical, Inc. (NASDAQ:ICUI) Receives $138.33 Consensus PT from Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has been given an average rating of “Moderate Buy” by the four research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $138.33.

Several brokerages recently commented on ICUI. Raymond James upped their target price on ICU Medical from $135.00 to $158.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. KeyCorp increased their price target on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th.

ICU Medical Stock Up 0.7 %

ICU Medical stock opened at $162.32 on Wednesday. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of -66.25 and a beta of 0.65. ICU Medical has a 52-week low of $78.28 and a 52-week high of $166.46. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm has a 50 day moving average price of $139.10 and a two-hundred day moving average price of $116.79.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. ICU Medical’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.58 earnings per share. Equities analysts predict that ICU Medical will post 3.76 EPS for the current year.

Insider Buying and Selling

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $17,096,771.78. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,552 shares of company stock valued at $4,537,802. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Truist Financial Corp bought a new position in shares of ICU Medical during the second quarter valued at about $310,000. Creative Planning increased its stake in ICU Medical by 75.5% in the 2nd quarter. Creative Planning now owns 3,906 shares of the medical instruments supplier’s stock valued at $464,000 after buying an additional 1,680 shares during the last quarter. Lighthouse Investment Partners LLC increased its stake in ICU Medical by 484.4% in the 2nd quarter. Lighthouse Investment Partners LLC now owns 62,826 shares of the medical instruments supplier’s stock valued at $7,461,000 after buying an additional 52,076 shares during the last quarter. Millennium Management LLC lifted its position in shares of ICU Medical by 327.8% during the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock worth $16,158,000 after buying an additional 104,264 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of ICU Medical in the 2nd quarter worth approximately $70,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.